This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Lenz, A. Articles by White, P. F. Search for Related Content PubMed PubMed Citation Articles by Lenz, A. Articles by White, P. F. Related Collections Pharmacology

---

ANESTHETIC PHARMACOLOGY

Emergency Use of Sugammadex After Failure of Standard Reversal Drugs

From the Department of Anesthesiology and Pain Management; University of Texas Southwestern Medical Center, Dallas, Texas.

Address correspondence and reprint requests to Paul F. White, MD, PhD, Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9068. Address e-mail to paul.white{at}utsouthwestern.edu.

Administration of sugammadex, 350 mg IV (4 mg/kg), in the postanesthesia care unit immediately (<60 s) relieved acute respiratory distress due to residual neuromuscular blockade in a 42-yr-old patient with chronic renal failure who had received vecuronium, 10 mg IV, for tracheal intubation, after inadequate reversal of neuromuscular blockade in the operating room with neostigmine, 5 mg IV, and glycopyrrolate, 1 mg IV.

This article has been cited by other articles:

				P. F. White, B. Tufanogullari, O. Sacan, E. G. Pavlin, O. J. Viegas, H. S. Minkowitz, and M. E. Hudson The Effect of Residual Neuromuscular Blockade on the Speed of Reversal with Sugammadex Anesth. Analg., March 1, 2009; 108(3): 846 - 851. [Abstract] [Full Text] [PDF]

				E. J. Rosman Pseudo-Emergent Use of an Investigational Drug Anesth. Analg., September 1, 2007; 105(3): 876 - 876. [Full Text] [PDF]

				P. M. Jones and T. P. Turkstra Urgent Usage of Sugammadex to Treat Residual Neuromuscular Blockade in the PACU Anesth. Analg., September 1, 2007; 105(3): 877 - 877. [Full Text] [PDF]

				P. F. White, G. Hill, and A. Lenz Where's the Fire? Anesth. Analg., September 1, 2007; 105(3): 878 - 878. [Full Text] [PDF]

				S. L. Shafer Pseudo-Emergent Use of an Investigational Drug Anesth. Analg., September 1, 2007; 105(3): 876 - 876. [Full Text] [PDF]

				A. Ziser Was It a True Emergency? Anesth. Analg., September 1, 2007; 105(3): 876 - 877. [Full Text] [PDF]

				D. Wax Where's the Fire? Anesth. Analg., September 1, 2007; 105(3): 877 - 878. [Full Text] [PDF]

				R. D. Miller Sugammadex: An Opportunity to Change the Practice of Anesthesiology? Anesth. Analg., March 1, 2007; 104(3): 477 - 478. [Full Text] [PDF]

				L. W. Schultheis and B. A. Rappaport The Food and Drug Administration Perspective: Use of an Investigational Drug in a Medical Emergency Anesth. Analg., March 1, 2007; 104(3): 479 - 480. [Full Text] [PDF]